2. Metabolic Enzyme/Protease
  3. Phosphodiesterase (PDE)
  4. Milrinone

Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 78415-72-2

사이즈 가격 재고 수량
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
25 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg 해외재고보유
500 mg 해외재고보유
1 g 해외재고보유
5 g   견적 받기  
10 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 33 publication(s) in Google Scholar

Other Forms of Milrinone:

Milrinone Related Antibodies

Top Publications Citing Use of Products

33 Publications Citing Use of MCE Milrinone

Cell Proliferation/Viability Assay
IF
Cell Imaging/Staining

    Milrinone purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Jul 28.  [Abstract]

    The GV oocytes from WT and Klhl8oo−/− female mice were cultured in M2 medium with Milrinone (2.5 μM) after Klhl8 mRNA microinjection (1000 ng/μL). Representative images of GV oocytes and maturation oocytes from WT and Klhl8oo−/− mice with or without Klhl8 mRNA injection were shown.

    Milrinone purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Dec 6;42(12):113531.  [Abstract]

    GV oocytes were cultured in M2 medium with Milrinone (2.5 mM; 24 h) for mRNA translation. Immunofluorescent staining showed expression of FLAG (green) and UHRF1 (red) in oocytes after injection of NC (control) and different NLRP14 mRNAs. The relative expression level of UHRF1 was measured.

    Milrinone purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2022 Dec 14;70(49):15570-15582.  [Abstract]

    The ovaries of mice were minced, and the naked oocytes (germinal vesicle (GV) stage) were removed under the microscope and washed three times in M2 medium containing 1/1000 Milrinone (2.5 μM).

    Milrinone purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2021 Dec 7;13(12):e14887.  [Abstract]

    GV oocytes were cultured in M2 medium with Milrinone (2.5 µM; 24 h) to prevent oocyte from undergoing germinal vesicle breakdown (GVBD).

    View All Phosphodiesterase (PDE) Isoform Specific Products:

    View All Isoforms
    PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

    • Biological Activity

    • Protocol

    • 순도&문서

    • References

    • 고객리뷰

    제품 설명

    Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

    IC50 & Target

    PDE3

     

    Cellular Effect
    Cell Line Type Value Description References
    HT-29 IC50
    > 50 μM
    Compound: Milrinone
    Growth inhibition of human HT-29 cells after 72 hrs by luminescent assay
    Growth inhibition of human HT-29 cells after 72 hrs by luminescent assay
    		[PMID: 19628397]
    Platelet IC50
    11 μM
    Compound: Milrinone
    Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method
    Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method
    		[PMID: 23425969]
    Platelet IC50
    12 μM
    Compound: Milrinone
    Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method
    Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method
    		[PMID: 23425969]
    Platelet IC50
    14 μM
    Compound: Milrinone
    Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method
    Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method
    		[PMID: 23425969]
    Platelet IC50
    38.5 μM
    Compound: Milrinone
    Antiplatelet activity against human platelet assessed as inhibition of collagen-induced platelet aggregation
    Antiplatelet activity against human platelet assessed as inhibition of collagen-induced platelet aggregation
    		[PMID: 20880705]
    Platelet IC50
    4.7 μM
    Compound: milrinone
    Inhibition of thrombin-induced platelet aggregation in human platelets after 5 mins by turbidimetric method
    Inhibition of thrombin-induced platelet aggregation in human platelets after 5 mins by turbidimetric method
    		[PMID: 18031002]
    In Vitro

    Milrinone (1 μM) increases PKA activity in hypoxic myocytes to normoxic levels. Milrinone (50 nM) normalizes TP receptor sensitivity in hypoxic myocytes by restoring PKA-mediated regulatory TP receptor phosphorylation[1]. Milrinone significantly reduces NE-induced vasoconstriction, attenuating both NE sensitivity and maximal tension generation. Inhibition of ATP-sensitive K+ channels or voltage-gated K+ channels do not prevent the milrinone-induced attenuation of NE responses[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Milrinone Related Antibodies
    In Vivo

    Milrinone (1 μg/kg/min, i.v.) significantly reduces PAP, PVR ( 18.96 ± 1.7%), and LAP ( 26.03 ± 2.3%) in congestive heart failure (CHF) rats. Milrinone (1 mg/mL, inhalation) results in a near-maximal reduction of PAP without significant effects on AP, decreases pulmonary artery pressure similarly in a larger collective of CHF rats. Milrinone inhalation selectively increases cAMP but not cGMP plasma concentrations in both groups. Repeated milrinone inhalations even reduce lung wet/dry weight ratio[2]. Milrinone (49.5 μg) largely shifts the ESPVR upwards and significantly increases end-systolic pressure (ESP(0.08)) and the systolic pressure-volume area (PVA(0.08)) at a mid-range LV volume (0.08 mL/g myocardium). Milrinone also slightly decreases LV ESP(ESV) and decreased Ea[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    분자량

    211.22

    화학식

    C12H9N3O
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC(N1)=C(C2=CC=NC=C2)C=C(C#N)C1=O
    선적

    Room temperature in continental US; may vary elsewhere.
    보관
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    용액&용해도
    In Vitro: 

    DMSO : 50 mg/mL (236.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.7344 mL 23.6720 mL 47.3440 mL
    5 mM 0.9469 mL 4.7344 mL 9.4688 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • 몰농도 계산기

    • 농도 희석 계산기

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.75 mg/mL (13.02 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.75 mg/mL (13.02 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    순도&문서

    Purity: 99.86%

    SDS (479 KB)

    COA (250 KB) RP-HPLC (206 KB) MS (243 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [2]

    In juvenile rats of 100 ± 8 g body weight (bw), CHF is induced by supracoronary aortic banding. In brief, rats are anesthetized by intraperitoneal injection of ketamine (87 mg/kg bw) and xylazine (13 mg/kg bw). Rats are placed in the supine position, the chest wall is shaved, and a left thoracotomy is performed in the third intercostal space during ventilation with 100% O2. The ascending aorta is freed from connective tissue and partially occluded by implantation of a titanium clip with a defined internal diameter of 0.8 mm. After surgical closure of the thorax, the rats are allowed to recover from anesthesia. For postoperative analgesia, rats receive 250 mg/kg bw of metamizole intramuscularly immediately after the operation and on the first postoperative day. Sham-operated rats serve as controls. After recovery from anesthesia, the animals are placed in cages with free access to water and standard laboratory diet. For inhalation, milrinone (0.2-5 mg/mL) or NaCl (0.9%) are nebulized using an ultrasonic nebulizer and inhaled for 3 min at identical peak inspiratory pressures as used throughout the experiment. A 3-min nebulization of 1 mg/mL milrinone results in vaporization of 14 μg of the phosphodiesterase-3 inhibitor as determined by microgravimetry. Therefore, the respective dose of 39 μg/kg is analog to inhaled doses in human studies. For intravenous delivery, milrinone (initial bolus of 2-10 μg/kg, followed by 0.2-1 μg/kg/min) or equivalent volumes of NaCl (0.9%; initial bolus of 1.6 mL/kg, followed by 10 μL/kg/h) are administered by an infusion pump for 10 min.

    MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.7344 mL 23.6720 mL 47.3440 mL 118.3600 mL
    5 mM 0.9469 mL 4.7344 mL 9.4688 mL 23.6720 mL
    10 mM 0.4734 mL 2.3672 mL 4.7344 mL 11.8360 mL
    15 mM 0.3156 mL 1.5781 mL 3.1563 mL 7.8907 mL
    20 mM 0.2367 mL 1.1836 mL 2.3672 mL 5.9180 mL
    25 mM 0.1894 mL 0.9469 mL 1.8938 mL 4.7344 mL
    30 mM 0.1578 mL 0.7891 mL 1.5781 mL 3.9453 mL
    40 mM 0.1184 mL 0.5918 mL 1.1836 mL 2.9590 mL
    50 mM 0.0947 mL 0.4734 mL 0.9469 mL 2.3672 mL
    60 mM 0.0789 mL 0.3945 mL 0.7891 mL 1.9727 mL
    80 mM 0.0592 mL 0.2959 mL 0.5918 mL 1.4795 mL
    100 mM 0.0473 mL 0.2367 mL 0.4734 mL 1.1836 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Milrinone Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Milrinone78415-72-2Win 47203Win47203Win-47203Phosphodiesterase (PDE)Inhibitorinhibitorinhibit

    최근 본 상품:

    온라인 문의

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Requested Quantity *

    고객명 *

    		 

    호칭

    메일주소 *

    		 

    전화번호 *

    Department

    		 

    회사명 *

    City

    도

    Country or Region *

    		      

    비고

    대량구매 문의

    Inquiry Information

    상품명:
    Milrinone
    Cat. No.:
    HY-14252
    수량:
    MCE Japan Authorized Agent:

    고객리뷰

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Lot #

    고객명 *

    		 

    메일주소 *

    전화번호

    		 

    Department *

    회사명 *

    		 

    Country or Region *

    비고

    SAFETY DATA SHEET (SDS)

    English - EN (479 KB) Français - FR (479 KB) Deutsch - DE (479 KB) Norwegian - NO (479 KB) Español - ES (479 KB) Swedish - SV (479 KB) Italian - IT (479 KB) Korean - KR (479 KB) Portuguese - PT (479 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.